Your Genes Are Not Your Destiny — But They Should Change Your Protocol

One of the most common things I hear from patients who have done genetic testing is some version of this: 'I got my results, I downloaded the raw data, and I have no idea what to do with it.' The testing has become accessible. The interpretation has not kept pace. What I want to offer here is a concrete example of how genetic findings should change clinical decisions — using my own profile, because I know it better than any de-identified case.

I had a comprehensive genetic analysis run through a clinical genomics platform that maps variants across multiple physiological systems. The findings were extensive. What follows is not an attempt to scare anyone about the complexity of their own genome — it's an attempt to show how this information, in the right clinical context, goes from abstract data to actionable protocol.

Start with methylation, because it is upstream of nearly everything. I carry the MTHFD1 1958 G>A variant in homozygous form — both copies. This is considered the highest-impact methylation variant in the 3x4 Genetics panel. The MTHFD1 enzyme functions in three steps of the folate cycle, and its impairment creates a global reduction in methylation capacity that cascades downstream. I also carry compound MTHFR variants — the 677 C>T and 1298 A>C polymorphisms — plus MTRR GG, which impairs methionine synthase recycling. The clinical implication is direct: standard folic acid is largely ineffective for me. The standard form has to be converted to 5-methyltetrahydrofolate before the body can use it, and the enzymes responsible for that conversion are precisely the ones that are impaired. I use 5-MTHF — the active, methylated form — as my folate supplement, and I require daily methylcobalamin rather than the cyanocobalamin found in most generic B-complex products. These are not expensive changes. But they are meaningless without the genetic context telling you why they matter.

The methylation impairment connects directly to my neurotransmitter profile in a way that took time to trace but is mechanistically clear. Dopamine converts to norepinephrine via an enzyme called DBH — dopamine beta-hydroxylase. DBH requires two cofactors to function: copper and ascorbate (vitamin C). Methylation impairment reduces the availability of those cofactors, creating what functions as a bottleneck in the dopamine-to-norepinephrine conversion step. My norepinephrine was confirmed low on a full neurotransmitter panel. The therapeutic intervention is not a dopamine agonist or a stimulant. It is vitamin C at 500 to 1000 mg per day in divided doses, and copper at 1 to 3 mg per day with attention to the zinc-to-copper ratio. That is a genomics-informed decision that looks nothing like a standard approach to fatigue or concentration difficulties.

On the cardiovascular side, my ACE DD genotype — a homozygous deletion polymorphism in the angiotensin-converting enzyme gene — means my renin-angiotensin-aldosterone system runs at a structurally higher level of activity. Elevated ACE activity drives higher angiotensin II, which stimulates aldosterone, which sustains adrenal demand. This is not just a blood pressure issue — it is one of the contributing factors to why my adrenal recovery has been harder and slower than it would be for someone without this architecture. My clinical response to this finding is spironolactone at 50 mg, which directly antagonizes aldosterone and addresses the downstream RAAS pressure. I also prioritize nitric oxide support — daily via a specialized lozenge — because I carry the eNOS Glu298Asp variant that reduces nitric oxide bioavailability independently.

The HLA findings are clinically notable in a different way. I carry both HLA DQ2.5 and HLA DQ8 — the two highest-risk haplotypes for celiac disease and gluten-mediated immune activation. Neither finding is diagnostic. But combined with stool findings showing intestinal permeability markers, the genomic data shifted my threshold for action. I am now fully gluten-free. Whether gluten was symptomatic before I removed it is impossible to know retroactively — but the genomic and functional evidence was sufficient to make the decision clearly.

The omega-3 finding is one of the most actionable in the entire panel, and one of the most commonly overlooked. I carry ELOVL2 CC in homozygous form — meaning the enzyme responsible for elongating omega-3 fatty acids into the long-chain forms EPA and DHA is significantly impaired. For most people, eating plant-based omega-3 sources like flaxseed or walnuts and relying on endogenous conversion is an acceptable approach. For me, it is not. I cannot efficiently make DHA from ALA. This means marine or algae-derived pre-formed EPA and DHA are not optional supplementation — they are a dietary requirement. The anti-inflammatory resolution pathways downstream of DHA production, including the synthesis of specialized pro-resolving mediators, are impaired without adequate pre-formed substrate. This finding changed what I eat and what I supplement, based entirely on a single enzyme variant.

The takeaway I want to leave with anyone who has done genetic testing or is considering it is this: the value is not in the raw data. It is in the clinical interpretation that connects variant findings to mechanism, and mechanism to intervention. Genetics does not tell you what disease you will get. It tells you how your particular biochemistry is likely to function — and where it needs support. Used well, it is the most personalized tool in medicine. Used poorly, it is an anxiety-inducing list of risks without context.

This is not medical advice. I'm sharing clinical experience and evidence to help you have better conversations with your provider.